Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

New biotechnologies for musculoskeletal injuries.

Andia I., Maffulli N.

Narrative Review on Osteoarthritis, Cartilage Damage, Tendon Injury, published in Surgeon (2018) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Surgeon (2018)
Country
Scotland
Reported sample size
—
Source database
PubMed
PMID
30170915
DOI
10.1016/j.surge.2018.08.004
Citations
39

Abstract (original English)

The practice of any sport is inherently associated with the risk of musculoskeletal lesions. We describe regenerative medicine technologies, including cellular therapies, gene therapies and multimolecular preparations of growth factors and cytokines, which are expected to advance the field of orthopaedics and sports medicine. Gene therapy involves the introduction of genetic information in the injured tissue to help that tissue to heal and, possibly, regenerate. Cell therapies used in clinical practice are based on the transplantation of adult human cells, which can be at different stages of differentiation. Currently, the stromal vascular fraction, containing stem cells and other niche components, has been injected in the articular cartilage of the knee or delivered via arthroscopy. Bone marrow concentrate (BMC) has been used to manage focal chondral defects via arthroscopy with promising clinical results. In addition, purified mesenchymal stem cells (MSCs) have been injected or delivered as an adjuvant to arthroscopic microfractures, and patients have shown improved clinical outcomes. Laboratory-expanded MSCs injected in osteoarthritis moderately improved pain and functional outcomes. MSC treatment in the form of stromal vascular fraction (SVF) or BMC or laboratory expanded adhesive cells (bone marrow and adipose derived stem cells, BM-MSCs and ADSCs) has been proven to be sa

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Athletic InjuriesBiomedical TechnologyCell- and Tissue-Based TherapyGenetic TherapyHumansMusculoskeletal SystemOrthopedicsRegenerationSports Medicine

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research